At TapImmune, Inc., we specialize in developing immunotherapies for a variety of cancers and infectious diseases designed to target tumors and metastatic disease. The company is working diligently to bring to market therapies for ovarian and breast cancer.
We are designing innovative vaccines that boost a patient’s own immune system to comprehensively stimulate their killer T-cells and helper T-cells to destroy cancer cells.
The company is currently conducting preclinical and clinical trials in breast and ovarian cancer to explore the promising commercial potential of its comprehensive approach to immunotherapy. In ovarian cancer, the development and commercial pathway has been facilitated by the granting of Orphan Drug Status and Fast Track Designation by the FDA.
Founded in 2006, TapImmune, Inc. is headquartered in Jacksonville, FL.